$NBIO ~ A successful course of Phase 1 trials will, in theory, eventually allow the company to bring the drug to market where it will have little in the way of serious competition given the poor outcomes currently defining the brain cancer treatment context. https://biopharmajournal.com/2020/09/29/why-n...close-look